Insmed (NASDAQ: INSM) reported Q3 EPS of ($1.10), $0.21 worse than the analyst estimate of ($0.89).

As of December 31, 2016, Insmed had cash and cash equivalents of approximately $163 million. The company's cash operating expenses for the second half of 2016 were $64 million, not including the $30 million upfront payment related to INS1007 and excluding depreciation and stock-based compensation expense. Insmed ended the fourth quarter of 2016 with $55 million in debt.

For earnings history and earnings-related data on Insmed (INSM) click here.